ALLERGAN USA, INC. for ALLERGAN USA, INC.

Copyright/Patent/Trademark CPT

Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); SENATE

Taxation/Internal Revenue Code TAX

Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.

Foreign entity interest: Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent that policy affects the tax treatment of its subsidiaries, foreign and domestic.

Contacted: SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); SENATE

Trade (domestic/foreign) TRD

Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO)

Medical/Disease Research/Clinical Labs MED

Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).

Contacted: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3204 (115th)

Pharmacy PHA

Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.

Contacted: Patent & Trademark Office (PTO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)